Aclaris Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Aclaris Therapeutics (ACRS).

Price Target Range — 10 Quarters

Analyst Consensus — 13 Analysts

11Buy

2Hold

Consensus RatingBuy# Analysts13Avg. Consensus PT$10Upside to Avg. PT+141.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 28, 2026	Wedbush	Martin Fan	PT Cut	Outperform	$10→$8
Oct 28, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$16
Sep 1, 2026	Canaccord Genuity	Edward Nash	Initiate	Buy	$10
Jun 2, 2026	LifeSci Capital	—	Initiate	Outperform	$13
May 5, 2026	Piper Sandler	Biren Amin	PT Raise	Overweight	$7→$11
May 5, 2026	Guggenheim	Seamus Fernandez	Initiate	Buy	$12
Apr 29, 2026	Wedbush	Martin Fan	PT Raise	Outperform	$8→$10
Apr 16, 2026	Oppenheimer	Jeff Jones	Initiate	Outperform	$10
Mar 31, 2026	Wedbush	Martin Fan	Maintained	Outperform	$8
Mar 19, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$16
Jan 28, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$16
Jan 21, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$16
Oct 20, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$16
Jul 10, 2025	Piper Sandler	Biren Amin	Assumes	Overweight	$6
Jun 25, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$16
May 28, 2025	Wedbush	Martin Fan	Initiate	Outperform	$8
May 14, 2025	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$20→$16
May 9, 2025	Scotiabank	Louise Chen	PT Cut	Sector Outperform	$15→$9
Mar 18, 2025	Cantor Fitzgerald	Prakhar Agrawal	Maintained	Overweight	—
Mar 7, 2025	Scotiabank	Louise Chen	Initiate	Sector Outperform	$15

Analyst Ratings News

PRO
Wedbush Maintains Outperform on Aclaris Therapeutics, Lowers Price Target to $8

Wedbush analyst Martin Fan maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform and lowers the price target from $10 to $8.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and maintains $16 price target.

Benzinga Newsdesk

PRO
Canaccord Genuity Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $10

Canaccord Genuity analyst Edward Nash initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Buy rating and announces Price Target of $10.

Benzinga Newsdesk

This Piper Sandler Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations From Tuesday

Top Wall Street analysts begin coverage of Aclaris Therapeutics, Orion Group Holdings, and Take-Two Interactive.

Avi Kapoor

PRO
Piper Sandler Maintains Overweight on Aclaris Therapeutics, Raises Price Target to $11

Piper Sandler analyst Biren Amin maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Overweight and raises the price target from $7 to $11.

Benzinga Newsdesk

This Applied Materials Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Citations for AMAT, BMEA, ACRS, KALU, SION.

Avi Kapoor

Aclaris Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Aclaris Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Wedbush Maintains Outperform on Aclaris Therapeutics, Lowers Price Target to $8

PRO
HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target

PRO
Canaccord Genuity Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $10

This Piper Sandler Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations From Tuesday

PRO
Piper Sandler Maintains Overweight on Aclaris Therapeutics, Raises Price Target to $11

This Applied Materials Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

People Also Watch

People Also Watch

Aclaris Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Aclaris Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWedbush Maintains Outperform on Aclaris Therapeutics, Lowers Price Target to $8

PROHC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target

PROCanaccord Genuity Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $10

This Piper Sandler Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations From Tuesday

PROPiper Sandler Maintains Overweight on Aclaris Therapeutics, Raises Price Target to $11

This Applied Materials Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

People Also Watch

People Also Watch

PRO
Wedbush Maintains Outperform on Aclaris Therapeutics, Lowers Price Target to $8

PRO
HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target

PRO
Canaccord Genuity Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $10

PRO
Piper Sandler Maintains Overweight on Aclaris Therapeutics, Raises Price Target to $11